drugset / Trial / NCT00291213

Levetiracetam Treatment of Tardive Dyskinesia

NCT00291213

Phase 3 Completed 50 enrolled Yale University UCB Pharma · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Timeline

Start
Primary completion
2006-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 500 mg
Subject Levetiracetam Other / unclassified 3000 mg

Indications